Bevacizumab in combination with immune checkpoint inhibitors for the treatment of unrecectable or metastatic highly microsatelite unstable or mismatch repair defective colorectal cancer: a muti-center, single-arm exploratory clinical study

ABSTRACT: Interventions: Case series:None Primary outcome(s): Objective remission rate Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2739485 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR